File(s) not publicly available
Reason: No enhanced material.
Linaclotide in constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: a profile of its use in the USA
online resourceposted on 09.04.2018 by Kate McKeage, Katherine A. Lyseng-Williamson
Any type of resource available online.
Compliance with Ethical Standards
Funding: The preparation of this review was not supported by any external funding.
Conflicts of interest: Kate McKeage is a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest
Additional information about this Adis Drug Review can be found here.
Linaclotide (Linzess) is a synthetic guanylate cyclase C agonist that acts locally in the gastrointestinal tract to increase intestinal fluid levels, increase colonic transit, and reduce peripheral pain. In adults with constipation-predominant irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC), once-daily oral linaclotide 290 lg (IBS-C), or 145 or 72 lg (CIC), significantly improved stool frequency and consistency, abdominal pain and bloating, and health-related quality-oflife. Linaclotide is generally well tolerated and, consistent with its therapeutic action, diarrhea is the most common adverse event. Access to the full article can be found here.
© Springer International Publishing AG, part of Springer Nature 2017